Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers
Open Access
- 6 August 2010
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 22 (2) , 341-347
Abstract
Background: To explore the influence of ovarian cancer histotype on the effectiveness of adjuvant radiotherapy (RT). Methods: A review of a population-based experience included all referred women with no reported macroscopic residuum following primary surgery who underwent adjuvant platin-based chemotherapy (CT), with or without sequential RT, and for whom it was possible to assign histotype according to the contemporary criteria. Results: Seven hundred and three subjects were eligible, of these 351 received RT. For those with apparent stage I and II tumors, the cohort with clear cell (C), endometrioid (E), and mucinous (M) disease who additionally received RT exhibited a 40% reduction in disease-specific mortality and a 43% reduction in overall mortality. Conclusions: The curability of those with stage I and II C-, E-, and M-type ovarian carcinomas was enhanced by RT-containing adjuvant therapy. This benefit did not extend to those with stage III or serous tumors. These findings necessitate reassessments of the role of RT and of the nonselective surgical and CT approaches that have characterized ovarian cancer care.Keywords
Funding Information
- National Cancer Institute of Canada (017051)
- Michael Smith Foundation for Health Research Unit (INRUA006045)
- sanofi aventis Canada Inc
- Eli Lilly Canada
This publication has 24 references indexed in Scilit:
- Lymph Node Metastasis in Grossly Apparent Stages I and II Epithelial Ovarian CancerInternational Journal of Gynecological Cancer, 2010
- The Impact of Complete Surgical Staging Upon Survival in Early-Stage Ovarian Clear Cell CarcinomaInternational Journal of Gynecological Cancer, 2009
- Intervals Longer Than 20 Weeks From Breast-Conserving Surgery to Radiation Therapy Are Associated With Inferior Outcome for Women With Early-Stage Breast Cancer Who Are Not Receiving ChemotherapyJournal of Clinical Oncology, 2009
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker StudiesPLOS Medicine, 2008
- Improved survival time: What can survival cure models tell us about population‐based survival improvements in late‐stage colorectal, ovarian, and testicular cancer?Cancer, 2008
- Summary and discussion of session recommendationsGynecologic Oncology, 2006
- Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapyInternational Journal of Gynecological Cancer, 2002
- Lymph Node Metastasis in Stage I Epithelial Ovarian CancerGynecologic Oncology, 2000
- Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in 'high-risk' epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade)International Journal of Gynecological Cancer, 1995
- 'Moderate-risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiationInternational Journal of Gynecological Cancer, 1994